The new broad agreement aims to deepen the already long-standing relationship between Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) and WuXi PharmaTech.
WuXi, already a preferred research services provider to J&JPRD for discovery chemistry, will now provide integrated research services in the area of discovery chemistry, discovery biology, chemical and analytical development services, formulation, and preclinical and bio-analytical services, to enhance drug discovery and shorten development timelines.
Ge Li, chairman and CEO of WuXi PharmaTech, said: “We are very pleased to expand our partnership with J&JPRD. This agreement leverages WuXi’s strong R&D capabilities from early stage discovery to commercial production to deliver reliable, high quality and cost-efficient services to J&JPRD. Our partnership demonstrates the strength of our innovation driven and fully integrated R&D service platform.”